Suzanne J. Hodgkinson

St. Vincent's Hospital
Darlinghurst, NSW, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 114 publications

Long-term efficacy of cladribine tablets: Results from the MAGNIFY-MS Extension study.

Long-term efficacy of cladribine tablets: Results from the MAGNIFY-MS Extension study.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: August 04, 2026

Multiple sclerosis outcomes after cancer diagnosis in people with recorded chemotherapy exposure: A real-world MSBase study.

Multiple sclerosis outcomes after cancer diagnosis in people with recorded chemotherapy exposure: A real-world MSBase study.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: August 03, 2026

Causal effects of multiple sclerosis therapies in left-truncated registry data.

Causal effects of multiple sclerosis therapies in left-truncated registry data.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: July 21, 2026

Comparative effectiveness of ofatumumab and ocrelizumab in relapsing multiple sclerosis: a target trial emulation using multinational registry data.

Comparative effectiveness of ofatumumab and ocrelizumab in relapsing multiple sclerosis: a target trial emulation using multinational registry data.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: April 28, 2026

A plain language summary on clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS study.

A plain language summary on clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS study.

Journal: Neurodegenerative disease management

Published: April 07, 2026

Treatment escalation after clinically silent MRI lesions in relapsing-remitting multiple sclerosis.

Treatment escalation after clinically silent MRI lesions in relapsing-remitting multiple sclerosis.

Journal: Brain : a journal of neurology

Published: March 12, 2026

Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study.

Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: January 13, 2026

Managing reactivation of multiple sclerosis during treatment with natalizumab.

Managing reactivation of multiple sclerosis during treatment with natalizumab.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: December 20, 2025

Cytokines Associated with Activation of CD4+CD25+Foxp3+ T Regulatory Cells.

Cytokines Associated with Activation of CD4+CD25+Foxp3+ T Regulatory Cells.

Journal: International journal of molecular sciences

Published: December 03, 2025

Comparative effectiveness of anti-CD20 therapies and S1P receptor modulators in late-onset multiple sclerosis: real-world evidence from the MSBase registry.

Comparative effectiveness of anti-CD20 therapies and S1P receptor modulators in late-onset multiple sclerosis: real-world evidence from the MSBase registry.

Journal: Therapeutic advances in neurological disorders

Published: November 09, 2025

Pregnancy-Related Disease Outcomes in Women With Moderate to Severe Multiple Sclerosis Disability.

Pregnancy-Related Disease Outcomes in Women With Moderate to Severe Multiple Sclerosis Disability.

Journal: JAMA network open

Published: September 15, 2025

Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study.

Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study.

Journal: CNS drugs

Published: September 04, 2025

Showing 1-12 of 114

Last Updated: 09/26/2026